Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
Discover how Rakovina Therapeutics leveraged its Enki AI platform to design novel inhibitors capable of crossing the blood-brain barrier to treat aggressive ...